JP2018523105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523105A5 JP2018523105A5 JP2017563088A JP2017563088A JP2018523105A5 JP 2018523105 A5 JP2018523105 A5 JP 2018523105A5 JP 2017563088 A JP2017563088 A JP 2017563088A JP 2017563088 A JP2017563088 A JP 2017563088A JP 2018523105 A5 JP2018523105 A5 JP 2018523105A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- subject
- crbn
- ratio
- therapeutic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170099P | 2015-06-02 | 2015-06-02 | |
| US62/170,099 | 2015-06-02 | ||
| US201562237905P | 2015-10-06 | 2015-10-06 | |
| US62/237,905 | 2015-10-06 | ||
| PCT/US2016/035198 WO2016196580A1 (en) | 2015-06-02 | 2016-06-01 | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523105A JP2018523105A (ja) | 2018-08-16 |
| JP2018523105A5 true JP2018523105A5 (enExample) | 2019-05-16 |
| JP6585737B2 JP6585737B2 (ja) | 2019-10-02 |
Family
ID=57441615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563088A Active JP6585737B2 (ja) | 2015-06-02 | 2016-06-01 | セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10338077B2 (enExample) |
| EP (1) | EP3304076A4 (enExample) |
| JP (1) | JP6585737B2 (enExample) |
| WO (1) | WO2016196580A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| AU2016326499A1 (en) | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| EP3422002B1 (de) | 2017-06-26 | 2020-04-08 | Bioscientia Institut für Medizinische Diagnostik GmbH | Screeningverfahren zur diagnose einer hämatologischen neoplasie |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN112912516A (zh) * | 2018-10-04 | 2021-06-04 | 阿尔佛雷德医疗集团 | 监测对治疗的反应的方法 |
| CN113490495B (zh) * | 2018-12-03 | 2024-09-27 | 达纳-法伯癌症研究公司 | Helios的小分子降解剂及其使用方法 |
| AU2019402189B2 (en) * | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US11366101B1 (en) | 2020-12-31 | 2022-06-21 | Elephas Biosciences Corporation | Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9662319B2 (en) | 2011-03-11 | 2017-05-30 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| CN104797256A (zh) * | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| WO2014179661A1 (en) * | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| BR112016012792A2 (pt) | 2013-12-06 | 2017-08-08 | Celgene Corp | Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras |
| JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US20180231561A1 (en) | 2015-08-12 | 2018-08-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| AU2016326499A1 (en) | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
-
2016
- 2016-06-01 WO PCT/US2016/035198 patent/WO2016196580A1/en not_active Ceased
- 2016-06-01 US US15/170,789 patent/US10338077B2/en active Active
- 2016-06-01 EP EP16804297.6A patent/EP3304076A4/en active Pending
- 2016-06-01 JP JP2017563088A patent/JP6585737B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Willumsen et al. | Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls | |
| JP2017524130A5 (enExample) | ||
| KR102571924B1 (ko) | c-MAF 상태에 기초한 유방암의 치료 | |
| Avram et al. | The density and type of MECA‐79‐positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma | |
| JP2013179945A (ja) | 分類予測を使用した肺障害についての診断 | |
| Ke et al. | Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria | |
| JP2016507066A5 (enExample) | ||
| Ward et al. | Evaluation of serum and tissue levels of VAP-1 in colorectal cancer | |
| CN106662543B (zh) | 肺癌患者中的非侵入性基因突变检测 | |
| Arakawa et al. | Clinical significance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell carcinoma | |
| US10585102B2 (en) | Characterization of cancer using detection of activated leukocyte cell adhesion molecule (ALCAM) shedding | |
| RU2011118477A (ru) | Способы и композиции для диагностики и лечения аутоиммунной болезни, возникающей вследствие рассеянного склероза | |
| JP2018529931A5 (enExample) | ||
| Edfeldt et al. | DcR3, TFF3, and midkine are novel serum biomarkers in small intestinal neuroendocrine tumors | |
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| Yan et al. | Significance of tumour cell HLA‐G5/‐G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients | |
| Štemberger et al. | Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma | |
| Roshdy et al. | Long non-coding RNA HOTAIR and HOTTIP as potential biomarkers for hepatitis C virus genotype 4-induced hepatocellular carcinoma | |
| Sun et al. | The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma | |
| Bakke et al. | Mucosal and faecal neutrophil gelatinase-associated lipocalin as potential biomarkers for collagenous colitis | |
| Srivastava et al. | Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer | |
| Liao et al. | Astrocyte elevated gene-1 (AEG-1) is a marker for aggressive salivary gland carcinoma | |
| Marioni et al. | Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is related to carcinoma recurrence rate and disease‐free survival | |
| Zhou et al. | Concurrent alterations of RAGE, RECK, and MMP9 protein expression are relevant to Epstein-Barr virus infection, metastasis, and survival in nasopharyngeal carcinoma | |
| González‐Santiago et al. | TGF‐β1 serum concentration as a complementary diagnostic biomarker of lung cancer: establishment of a cut‐point value |